pharmachologic effect

Selective β2-adrenergic receptor agonist. In therapeutic doses, it acts on the β2-adrenoreceptors of the smooth muscles of the bronchi and has a short (4 to 6 hours) bronchodilator effect on β2-adrenergic receptors with a rapid onset of action (within 5 minutes) with reversible airway obstruction.

Has a pronounced bronchodilator effect, preventing or arresting bronchospasm, reduces resistance in the airways. Increases the STR. Increases mucociliary clearance (with chronic bronchitis to 36%), stimulates the secretion of mucus, activates the functions of ciliated epithelium.

In recommended therapeutic doses does not have a negative effect on the cardiovascular system, does not cause an increase in blood pressure. To a lesser degree, in comparison with the drugs of this group, it has a positive chrono and inotropic effect. Causes the enlargement of the coronary arteries.

It has a number of metabolic effects: it reduces the concentration of potassium in the plasma, affects glycogenolysis and insulin secretion, has hyperglycemic (especially in patients with bronchial asthma) and a lipolytic effect, increases the risk of acidosis.

Indications

Bronchial asthma:

- relief of symptoms of bronchial asthma when they occur;

- prevention of bouts of bronchospasm associated with exposure to an allergen or caused by physical exertion;

- use as one of the components with prolonged maintenance therapy of bronchial asthma.

Other chronic lung diseases accompanied by reversible airway obstruction, including chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema.

Bronchodilators should not be the only or main component of asthma therapy for unstable or severe flow. If there is no response to salbutamol in patients with severe bronchial asthma, it is recommended to perform SCS therapy to achieve and maintain disease control. The lack of response to salbutamol therapy may indicate the need for an urgent medical consultation or treatment.